Member Info for chester18

Yes its quiet on here but most of us that were here before were looking forward to the funding issue being sorted and the SP moving to 2p or 3p.

It will take a while for that bad taste to go away... ....yuk... still taste it... : )

I'm surprised that the SP is sticking around the 0.35 / 0.36 mark. At this price based on what the company now have in cash and the volume of committed orders I would have expected some large buyers mopping up the loose 0.25p sellers.

I've bought everything I wanted already but if I still had something the kitty I would definitely buy some more and I'm not ramping it's the truth.

It's hard to judge but with some good announcements from the company we should be around 0.5p by the end of September but it all depends on that news flow.

Chester.

Sorry I flipped between two of my holdings that last post should be on TRX. My apologies to all the RENE board readers.

Chester

Yes it is quiet but most of us that were here before were looking forward to the funding issue being sorted and the SP moving to 2p or 3p.

It will take a while for that bad taste to go away... ....yuk... still taste it... : )

I'm surprised that the SP is sticking around the 0.35 / 0.36 mark. At this price based on what the company now have in cash and the volume of committed orders I would have expected some large buyers mopping up the loose 0.25p sellers.

I've bought everything I wanted already but if I still had something the kitty I would definitely buy some more and I'm not ramping it's the truth.

It's hard to judge but with some good announcements from the company I would expect us to be around 0.5p by the end of September but it's all down to news flow.

Chester.

Hi Balerno1

The news piece in the FT.COM says the researchers are from the University of California San Diego.

They switch off a protein called 'PTB' that then raised the number of Neurons by a third and restored dopamine production. Having read that article and a couple of others there is no mention of the use of Exosomes.

Our first collaboration was with a US Bio-Pharmaceutical Co the second with a US Pharmaceutical Co and today's announcement is said to be with a US Bio-Technology Co. No mention of University research departments.

Chester.

It certainly seems quieter. What we need now is a stonking RNS to enthuse investors and highlight the fact that the company is positively breaking new ground on both customer sales and planning the new manufacturing plant.

Gareth Jones, Interim CEO said in the recent RNS :

"As an example of the exciting growth potential of the business and testament to the strong underlying demand for our portfolio of regenerative biologic products, following the year-end, we announced a strategic partnership with a top 10 global healthcare company for a new product launch. Additionally, the receipt of CE Mark approval for OrthoPure XT is a significant milestone in the evolution of our product portfolio and corporate objectives".

So updates on these items will help build the SP back towards 1.0p, but its only been a few weeks so patience needed.

Chester.

Morning Clivealive

I'm not sure we can put those two pieces of news together. The story from California is probably nothing to do with Exosomes. There are hundreds of companies in the US working on novel drugs for Parkinsons and the like.

For this to involve Reneurons Exosomes it would have to be that very first collaboration and I'm not sure that there is enough evidence of a link.

Don't get me wrong I will be more that happy if it is. I will do some research.

Chester.

Great news that we've signed another collaboration that's now three on the go.

I still feel that we will hear something with more gravitas in the next 3 - 4 weeks as we get closer to the year end report.

As I have said the January 2019 collaboration agreement has had long enough to establish if it works or not.

Chester.

Hi GrizzlyB

Good question, a milestone payment from Fosun Pharma would be good to fill up the bank account but in a way not what I'm hoping for as we know that it is a very real possibility and not a new pharma co showing interest.

Also if it is Fosun who are showing special interest in Exosomes, it's good but it's bad, because they will need at least 12 months to evaluate and we really need a wider validation of our platforms if we can.

With Fosun it would be all our eggs on one basket.

We signed the first Exosomes collaboration with a US biopharmaceutical company in Jan 2019 for synthetic oligonucleotides, to optimise their loading into exosomes. If there is a successful outcome a license agreement will be agreed. That's the one I would like it to be.

Or another large deal for RP and CTX say in Japan or the like but I think that's unlikely.

Chester.

Knowlesi

You are the ultimate bender of the facts....

Are you actually invested in Scancell the Immunology Research and Development company or do you still believe they operate on the high street and sell something akin to photocopiers.
Because you talk and post like a you have an axe to grind with anyone who has any patience or intellectual capacity to realise that in this case, an R&D company, the road is never straight, a lot like your posts.

Chester.

And who are the three not-rights that recommend such a fabrication of the truth.....

I truly worry for the metal health of our species....

Chester.

Not for at least 18 months. TRX don't need the expense or the distraction.

All management effort will be sharply focused on dealing with the new manufacturing facility in San Antonio and matching production to the growing business.

Only when they are on top of those tasks and their thoughts turn to a US listing will consolidation be on the priority list.

Chester.

Hi Ratcliffewriter

Proper research and a balanced diet....sorry,
I mean a balanced debate....... :)

Chester.

Hi Knowlesi

I've just checked that as well.

They sold 223,000 OXB at £8.08 raising £1.8m

They have only bought 60,000 OBD at 50p which is only £30k .

Vulpes must have some ulterior motive for raising £1.8m in cash......

Ummmm.....

Chester.

Just to be clear on how fast acting Modi1 is.

If it's working 100% in a patient are we talking about measurable reduction in the tumour in days or a few weeks?

Chester

Absolutely fantastic news. Until this RNS there was always 'what if'.

No 'what ifs' anymore we have Modi 1 on the launch pad and this incredible vanquisher of cancer cells is preparing to kick up a storm.

And Yep, if you can't tell I'm pretty excited about getting both of our trials Started..........

Chester.

Really hopeful that we'll hear some pivitol news next month as part of the year end report or at the AGM.

They have parked the CTX programme with partners because they were advised or shall we say urged to prioritise RP and Exosomes.

I'm pinning my hope's on our first Exosomes deal. The first collaboration was penned in January 2019 so plenty of time has past to be thoroughly tested in the labs.

Chester.

Looks like all the .3549p and above are probably buys. You can never quite tell and thats just how the Market Makers like it.

It's just a matter of being patient until all the less than sticky shares have been sold.
The big catalyst here will be positive informative news from the company.

Chester.

Hi Ruck

Just making the point that in their calculations they could have used any figure.
I put 9.65% to reinforce that point.

The 10% as you mention is still just an arbitrary number approximate to the relevent data.

Chester.

Ruck,

So Trinity Delta suggest that a successful SCIB1 Combi with Keytruda is worth 3.8p.
Based on the current number of shares 465,000,000 that equates to £17.67m.

But what does that mean, how many variant guesses have they had to make to come up with that figure. Maybe they used 9.65% of Keytruda use is in Melanoma but that in its self is a judgement of how many potential patients would be suitable.

My point is that to define what a successful SCIB1 trial could be worth is a totally random guess at this moment in time.

So let's just agree that it would make a significant difference to the SP, the spike in sentiment and euphoria of the market could reach £1.50 or only 65p there is no way of knowing beforehand.

Now big Pharma wanting to buy the platform would entail what was the effective percentage in the trial data, what is the current global £ for that indication worth, what the future potential could be and what are the possible future developments .

Try working that one out.

What it is worth, an impossible question with no proveable answer.

Chester.

No I just think it's down to future prospects.
Their will be some who see .37p as a great opportunity to hold for .74p and top slice 50% giving them a free holding of half of those shares.

My milestones are next years 2020 full years results where I expect a good upturn in sales and news that the 2nd manufacturing facility is up and running full tilt.

After that its news on deals, new products and approvals.

In no rush now but will feel better when we get back around .65p to .75p as it will show the company is back on track.

Chester.